Table 3.
Summary of ongoing clinical trials for gene-based diagnosis.
| No | NCT Number | Official Title | Brief Summary | Types of Liver Tumors | Phase | Enrollment | Current Status and Results | Ref. |
|---|---|---|---|---|---|---|---|---|
| 1 | NCT00373737 | Microarray Analysis of Gene Expression in Liver Tumors | This study aims to study the gene expression profiles of liver tumors to help us understand their biology, and to find new tumor and treatment markers for liver cancer. | Liver Cancer | Not Applicable | 300 | Completed No results reported to date | |
| 2 | NCT01786980 | The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene | This study aimed to obtain the important factors affecting liver cancer prognosis, survival, recurrence and metastasis in order to be able to find and establish the effective prognostic evaluation method by analyzing clinical information combining the information of gene chip, methylation chip and flow cytometry to carry out comprehensive researches on liver cancer cell genetics, epigenetics, stem cells and tumor microenvironment changes. | HCC | Not Applicable | 300 | Completed No results reported to date | |
| 3 | NCT00160940 | Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease | This study aimed to find the genes that are expressed in both the circulating white blood cells and the liver of patients, using differential gene expression analysis, with varying degrees of liver damage of different causes with or without liver cancers. | Primary Liver Cancers Metastatic Liver Tumors | Not Applicable | 200 | Recruiting No results available | |
| 4 | NCT01643499 | A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies | This study aimed to determine the dose of a chemotherapy drug (irinotecan) in 1st cycle in each of two UGT1A1 genotype groups (*1*1, *1*28) using genotype-guided dosing, that can be tolerated as part of a combination of drugs. | HCC CCC Metastatic Liver Tumors | 1 | 79 | Active, not recruiting Estimated Completion Date: Apr, 2019 | |
| 5 | NCT02465060 | Molecular Analysis for Therapy Choice (MATCH) | This phase II MATCH trial aimed to study how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. | Primary Liver Cancers Metastatic Liver Tumors | 2 | 6452 | Recruiting No results available Estimated Primary Completion Date: June, 2022 | |
| 6 | NCT02733809 | Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | This study aimed to clarify the hypothesis that resistant tumor may be due to genetic mutations and/or other alternative pathways that could be the reason to overcome the SOR and still proliferate by analyzing the gene expression profiling signature (a set of dysregulated genes) for molecular classification, diagnosis, and prognosis of several types of cancers. | HCC | 4 | 40 | Recruiting No results available Estimated Completion Date: Dec, 2024 | [169] |
| 7 | NCT01752920 | A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion | This open-label, Phase 1/2, dose escalation and signal finding study aimed to clarify the effect of Derazantinib (ARQ 087), multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases, in the cases with cholangiocarcinoma with FGFR2 gene alterations. | CCC | 1/2 | 119 | Completed Results partly reported | [170] |
| 8 | NCT03993873 | A Phase 1, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0022, a Novel MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET | A phase 1, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced solid tumors harboring genetic alterations in MET. The study will proceed in three parts: a dose-escalation, a food effect, and dose-expansion. | Advanced Solid Tumor Metastatic Solid Tumors | 1 | 120 | Recruiting No results available Estimated Completion Date: Nov, 2023 | |
| 9 | NCT01892072 | VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway | This study aimed to examine the VEGF signaling in HCC cell lines and its mechanism in HCC growth, proliferation and apoptosis. | HCC | Not Applicable | 50 | Active, not recruiting | |
| 10 | NCT02507882 | Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma | This study aimed to determine through investigating a cohort of 405 patients, whether IL28B rs12979860 and rs4803217 polymorphisms are associated to the risk of HCC in chronic hepatitis C patients. | HCC | Not Applicable | 405 | Not yet recruiting | |
| 11 | NCT00858000 | Analysis of the Incidence of Expression of a Specific Set of Genes and of Tumor Antigens in Cancer Tissue From Patients With Hepatocellular Carcinoma | This study aimed to analyze the expression of specific markers in HCC and tumor-related antigens to develop new approaches to treat this type of cancer with genetic immunotherapy. | HCC | Not Applicable | 30 | Completed No results reported to date | |
| 12 | NCT03722628 | The Assessment of Matrix Metalloproteinase-1 Genotypes Polymorphism as a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients With Liver Cirrhosis | This study aimed to assess whether the Matrix Metalloproteinase-1 genotypes polymorphism can be a risk factor for HCC in chronic hepatitis C patients with liver cirrhosis. | HCC | Not Applicable | 200 | Not yet recruiting | [172] |
| 13 | NCT01930383 | Circulating Tumor Cells as Biomarkers of Prognosis and Predictors of Efficacy of Drug Therapy for Patients With Hepatocellular Carcinoma | This study aimed to explore the clinical value of correlation between circulating tumor cells numbers and other clinical characteristics in HCC patients with different stages. | HCC | Not Applicable | 150 | Recruiting No results available | |
| 14 | NCT00619541 | Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma. | The purpose of this study is to use SOR + 5-FU to evaluate activity, efficacy, safety, pharmacodynamics and pharmacokinetics in patients with advanced HCC. | HCC | 2 | 46 | Completed Results partly reported | [173] |
HCC, hepatocellular carcinoma; FOLFIRINOX regimen A regimen consisting of leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin; SOR, sorafenib; FGFR, fibroblast growth factor receptor; CCC, cholangiocellular carcinoma.